GlassScriptPhysician profile
David A Fost
NPI 1356339410
$12,968.42
in general payments reported to CMS, 2019-2025
23 companies · $1,736 in 2025
The $1,736 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,634 · 2020: $723 · 2021: $283 · 2022: $366 · 2023: $4,851 · 2024: $1,377 · 2025: $1,736.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,645 · Food and Beverage: $3,459 · Travel and Lodging: $712 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,645.00 |
| Food and Beverage | $3,458.87 |
| Travel and Lodging | $711.52 |
| Education | $148.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $4,570.73 | 2019-2025 | Xolair |
| Pfizer INC. | $3,535.89 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,190.11 | 2021-2025 | Airsupra, Tezspire, Breztri |
| Regeneron Healthcare Solutions, INC. | $872.59 | 2020-2025 | Dupixent |
| Genzyme Corporation | $613.54 | 2020-2025 | |
| Glaxosmithkline, LLC. | $514.68 | 2020-2025 | Nucala |
| Eyevance Pharmaceuticals LLC | $500.00 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $322.84 | 2025 | Neffy |
| Optinose US, INC. | $245.26 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $165.28 | 2024-2025 | Cuvitru, Eohilia |
| Sanofi-Aventis U.S. LLC | $98.99 | 2025 | |
| Amgen INC. | $96.69 | 2024-2025 | Tezspire |
| Kaleo, INC. | $41.36 | 2022 | |
| Novartis Pharmaceuticals Corporation | $37.77 | 2024-2025 | |
| Aerin Medical INC. | $37.17 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $34.00 | 2024-2025 | Ryaltris |
| Leo Pharma INC. | $27.46 | 2022-2023 | Adbry |
| Aimmune Therapeutics, INC. | $27.24 | 2020 | |
| Cycle Pharmaceuticals INC | $21.35 | 2024 | Sajazir |
| Circassia INC. | $15.47 | 2020 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Fost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.